Chemical formula: C₁₉H₁₈F₃N₃O₂ Molecular mass: 377.367 g/mol PubChem compound: 11610526
Lasmiditan binds with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown.
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| REYVOW Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Lasmiditan is an active ingredient of these brands:
United States (US)Austria (AT)Croatia (HR)Estonia (EE)France (FR)Ireland (IE)Italy (IT)Japan (JP)Lithuania (LT)Spain (ES)Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
